KR102544465B1 - 신규 화합물 및 그의 치료 용도 - Google Patents

신규 화합물 및 그의 치료 용도 Download PDF

Info

Publication number
KR102544465B1
KR102544465B1 KR1020197010569A KR20197010569A KR102544465B1 KR 102544465 B1 KR102544465 B1 KR 102544465B1 KR 1020197010569 A KR1020197010569 A KR 1020197010569A KR 20197010569 A KR20197010569 A KR 20197010569A KR 102544465 B1 KR102544465 B1 KR 102544465B1
Authority
KR
South Korea
Prior art keywords
dab
compound
formula
conh
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197010569A
Other languages
English (en)
Korean (ko)
Other versions
KR20190064592A (ko
Inventor
멜라니 글로솝
크리스틴 왓슨
미카엘 웨스트비
Original Assignee
센타우리 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615560.8A external-priority patent/GB201615560D0/en
Priority claimed from GBGB1707076.4A external-priority patent/GB201707076D0/en
Application filed by 센타우리 테라퓨틱스 리미티드 filed Critical 센타우리 테라퓨틱스 리미티드
Publication of KR20190064592A publication Critical patent/KR20190064592A/ko
Application granted granted Critical
Publication of KR102544465B1 publication Critical patent/KR102544465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197010569A 2016-09-13 2017-09-13 신규 화합물 및 그의 치료 용도 Active KR102544465B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1615560.8A GB201615560D0 (en) 2016-09-13 2016-09-13 Novel compounds and therapeutic uses thereof
GB1615560.8 2016-09-13
GBGB1707076.4A GB201707076D0 (en) 2017-05-04 2017-05-04 Novel compounds and therapeutic uses thereof
GB1707076.4 2017-05-04
PCT/GB2017/052699 WO2018051085A1 (en) 2016-09-13 2017-09-13 Novel compounds and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
KR20190064592A KR20190064592A (ko) 2019-06-10
KR102544465B1 true KR102544465B1 (ko) 2023-06-19

Family

ID=59923474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010569A Active KR102544465B1 (ko) 2016-09-13 2017-09-13 신규 화합물 및 그의 치료 용도

Country Status (13)

Country Link
US (1) US11014966B2 (https=)
EP (1) EP3512544B1 (https=)
JP (2) JP7185622B2 (https=)
KR (1) KR102544465B1 (https=)
CN (1) CN110022896B (https=)
AU (1) AU2017328896B2 (https=)
BR (1) BR112019004877A2 (https=)
DK (1) DK3512544T3 (https=)
ES (1) ES2854991T3 (https=)
IL (1) IL265269B (https=)
MX (1) MX2019002879A (https=)
WO (1) WO2018051085A1 (https=)
ZA (1) ZA201901422B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201804098D0 (en) * 2018-03-14 2018-04-25 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201904534D0 (en) * 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
WO2025236916A1 (en) * 2024-05-16 2025-11-20 Brii Biosciences, Inc. Compositions and methods for treating infections
GB202410052D0 (en) * 2024-07-10 2024-08-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP1594898A2 (en) * 2003-02-06 2005-11-16 Tripep AB Glycosylated specificity exchangers
CA2517396A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2016104647A1 (ja) 2014-12-25 2016-06-30 国立大学法人大阪大学 糖鎖結合ワクチン抗原及び糖鎖導入剤
GB201517859D0 (en) 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
US11014966B2 (en) 2021-05-25
EP3512544A1 (en) 2019-07-24
EP3512544B1 (en) 2020-10-28
KR20190064592A (ko) 2019-06-10
AU2017328896B2 (en) 2024-07-25
US20190248838A1 (en) 2019-08-15
JP2022184922A (ja) 2022-12-13
BR112019004877A2 (pt) 2019-06-11
NZ751662A (en) 2025-05-02
JP7185622B2 (ja) 2022-12-07
ES2854991T3 (es) 2021-09-23
MX2019002879A (es) 2019-09-18
JP2019526614A (ja) 2019-09-19
CN110022896A (zh) 2019-07-16
WO2018051085A1 (en) 2018-03-22
CA3036405A1 (en) 2018-03-22
CN110022896B (zh) 2023-12-19
IL265269B (en) 2022-04-01
IL265269A (en) 2019-05-30
AU2017328896A1 (en) 2019-04-04
DK3512544T3 (da) 2021-02-01
ZA201901422B (en) 2020-11-25

Similar Documents

Publication Publication Date Title
KR102544465B1 (ko) 신규 화합물 및 그의 치료 용도
KR102855963B1 (ko) 아시네토박터 바우만니이에 대한 펩티드 마크로사이클
US12138292B2 (en) Compounds and therapeutics uses thereof
CN108472381B (zh) 化合物及其治疗用途
JP2018531287A6 (ja) 化合物及びそれらの治療用途
US20220162262A1 (en) Novel compounds and therapeutic uses thereof
US20210085798A1 (en) Immunity linker molecules and their use in the treatment of infectious diseases
CA3036405C (en) Novel compounds and therapeutic uses thereof
HK40011971B (en) Peptide compounds and therapeutic uses thereof
HK40011971A (en) Peptide compounds and therapeutic uses thereof
EA038112B1 (ru) Новые соединения и их терапевтические применения
EP3606558B1 (en) Novel compounds and therapeutic uses thereof
WO2025238360A1 (en) Novel compounds and therapeutic uses thereof
WO2026013391A1 (en) Novel compounds and therapeutic uses thereof
CA3001084C (en) Aptamer or biotin conjugates for the treatment of cancer or infectious diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200911

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220525

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221216

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220525

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20221216

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220725

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200911

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230322

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230308

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20221216

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220725

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200911

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230613

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration